[
  {
    "info": {
      "NCT": "NCT03833154",
      "Protocol_No": "D9103C00001",
      "jit": "Tempus",
      "trial_name": "AstraZeneca PACIFIC-4 (D9103C00001)"
    },
    "disease": {
      "summary": "Radiation Therapy in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC)  | Unresected NSCLC Harboring an EGFR Mutation  ",
      "details": [
        {
          "code": "Non-Small Cell Lung Cancer (NSCLC)",
          "selection": "include"
        }
      ]
    },
    "query": {
      "nct": "NCT03833154",
      "title": "Durvalumab vs Placebo With Stereotactic Body Radiation Therapy in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation",
      "current_status": "Recruiting",
      "status_verif_date": "August 2022",
      "last_update_date": "August 29, 2022",
      "trial_hold_status": "open",
      "sponsor": "AstraZeneca",
      "brief_summary": "This is a Phase III, randomized, placebo-controlled, double-blind, multi-center study assessing the efficacy and safety of durvalumab with SoC SBRT versus placebo with SoC SBRT in patients with unresected clinical Stage I/II lymph node-negative (T1 to T3N0M0) NSCLC.\n\nAn additional cohort will assess Osimertinib following SBRT in patients with early stage unresected T1 to T3N0M0 NSCLC harbouring an EGFR mutation.",
      "conditions": "Carcinoma, Non-Small-Cell Lung",
      "type": "Interventional",
      "phase": "Phase 3",
      "arm": [
        {
          "ArmID": "1",
          "cohortlabel": "SoC SBRT + Durvalumab Therapy (Main Cohort)",
          "drug": "Durvalumab",
          "arm_type": "Experimental",
          "line_of_therapy": "Not available",
          "arm_hold_status": "open",
          "biomarker": [
            {
              "cohort": "SoC SBRT + Durvalumab Therapy (Main Cohort)",
              "Gene": "EGFR",
              "Gene2": "Not available",
              "Type": "Mutation",
              "Variant": "Not available",
              "Selection": "exclude",
              "Function": "Not available",
              "summary": "EGFR Mutation  "
            }
          ]
        },
        {
          "ArmID": "2",
          "cohortlabel": "SoC SBRT + Placebo Therapy (Main Cohort)",
          "drug": "Other: Placebo",
          "arm_type": "Placebo Comparator",
          "line_of_therapy": "Not available",
          "arm_hold_status": "open",
          "biomarker": [
            {
              "cohort": "SoC SBRT + Placebo Therapy (Main Cohort)",
              "Gene": "EGFR",
              "Gene2": "Not available",
              "Type": "Mutation",
              "Variant": "Not available",
              "Selection": "exclude",
              "Function": "Not available",
              "summary": "EGFR Mutation  "
            }
          ]
        },
        {
          "ArmID": "3",
          "cohortlabel": "SoC SBRT + Osimertinib Therapy (Osimertinib cohort, single-arm, separate cohort)",
          "drug": "Osimertinib (single-arm, open-label)",
          "arm_type": "Experimental",
          "line_of_therapy": "Not available",
          "arm_hold_status": "open",
          "biomarker": [
            {
              "cohort": "SoC SBRT + Osimertinib Therapy (Osimertinib cohort, single-arm, separate cohort)",
              "Gene": "EGFR",
              "Gene2": "Not available",
              "Type": "Mutation",
              "Variant": "L858R",
              "Selection": "include",
              "Function": "Not available",
              "summary": "EGFR-TKI sensitivity L858R Mutation  "
            },
            {
              "cohort": "SoC SBRT + Osimertinib Therapy (Osimertinib cohort, single-arm, separate cohort)",
              "Gene": "EGFR",
              "Gene2": "Not available",
              "Type": "Mutation",
              "Variant": "Ex19del",
              "Selection": "include",
              "Function": "Not available",
              "summary": "EGFR-TKI sensitivity Ex19del Mutation  "
            }
          ]
        }
      ],
      "docs": "Q:/MCK/MOA/Precision Oncology/JIT Trials/Tempus JIT_2022-08-08.docx",
      "min_age": "18 Years",
      "gender": "All",
      "link": "<a href=\"https://clinicaltrials.gov/ct2/show/NCT03833154\" target=\"_blank\">NCT03833154<\/a>"
    }
  }
]
